Apalutamide (NCT06067269)

Name: Apalutamide trial for Prostate Adenocarcinoma (NCT06067269)
Uploaded: 2026-10-31T21:34:59.166Z
Duration: 1 min 26 s
Description: Apalutamide trial for Prostate Adenocarcinoma (NCT06067269). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06067269.

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial: a one-minute explainerNCT060672691 min

Apalutamide trial for Prostate Adenocarcinoma (NCT06067269). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult men with unfavorable intermediate-risk prostate adenocarcinoma, a Decipher genomic score, and an MRI-visible prostate lesion. PSMA imaging is required; previous pelvic radiation excludes participation.

The idea: apalutamide blocks testosterone signaling while precisely targeted radiation treats the prostate. Patients take apalutamide daily for six or twelve months and receive five radiation treatments over one–two weeks. Radiation intensity varies between involved and uninvolved areas. Researchers measure PSA response and side effects.

This phase 2 study plans 95 patients. Amar Kishan leads at UCLA, Los Angeles, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.